A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Tareq Salous,Nikhil A Shukla,Sandra K Althouse,Susan M Perkins,Muhammad Furqan,Ticiana Leal,Anne M Traynor,Lawrence E Feldman,Nasser H Hanna,Greg A Durm

Cancer（2023）

引用 3|浏览17

暂无评分

摘要

Pembrolizumab plus next-line chemotherapy in patients with advanced NSCLC who experienced PD after a clinical benefit from a CPI was associated with statistically significant higher PFS in comparison with historical controls of single-agent chemotherapy alone.

查看译文

关键词

docetaxel,non-small cell lung cancer,pembrolizumab,pemetrexed,second-line chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要